BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Roivant Sciences Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Roivant Sciences Ltd.'s drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07333183-544@assetmemo.bio
DTSTAMP:20261121T005747Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Mosliciguat: Phase 2 readout est. (NCT07333183)
DESCRIPTION:Mosliciguat\, phase 2\, Pulmonary Hypertension Associated with 
 Interstitial Lung Disease.\nStudy: A Study of Mosliciguat in Combination W
 ith Inhaled Treprostinil in PH-ILD\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/mosliciguat#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073331
 83
URL:https://assetmemo.bio/drug/mosliciguat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018323-10825@assetmemo.bio
DTSTAMP:20261121T005747Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Imeroprubart: Phase 2 readout est. (NCT07018323)
DESCRIPTION:Imeroprubart\, phase 2\, Graves' Disease.\nStudy: A Study to As
 sess the Efficacy\, Safety\, and Tolerability of IMVT-1402 as Treatment fo
 r Adult Participants With Graves' Disease\nEstimated primary completion: M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/imeroprubart
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 18323
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06754462-10825@assetmemo.bio
DTSTAMP:20261121T005747Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Imeroprubart: Phase 2 readout est. (NCT06754462)
DESCRIPTION:Imeroprubart\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study 
 to Evaluate the Efficacy\, Safety\, and Tolerability of IMVT-1402 in Adult
  Participants With Active\, Difficult to Treat Rheumatoid Arthritis\nEstim
 ated primary completion: September 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/imeroprubart#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06754462
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07039916-10825@assetmemo.bio
DTSTAMP:20261121T005747Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Imeroprubart: Phase 3 readout est. (NCT07039916)
DESCRIPTION:Imeroprubart\, phase 3\, Myasthenia Gravis.\nStudy: Study to As
 sess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Sev
 ere Generalized Myasthenia Gravis\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/imeroprubart#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070399
 16
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06727604-10825@assetmemo.bio
DTSTAMP:20261121T005747Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Imeroprubart: Phase 2 readout est. (NCT06727604)
DESCRIPTION:Imeroprubart\, phase 2\, Graves' Disease.\nStudy: A Study to As
 sess the Efficacy\, Safety\, and Tolerability of IMVT-1402 as Treatment fo
 r Adult Participants With Graves' Disease\nEstimated primary completion: J
 une 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/imeroprubar
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 727604
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979531-10825@assetmemo.bio
DTSTAMP:20261121T005747Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Imeroprubart: Phase 2 readout est. (NCT06979531)
DESCRIPTION:Imeroprubart\, phase 2\, Sjögren's Disease.\nStudy: Efficacy a
 nd Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Diseas
 e With Moderate to Severe Systemic Disease Activity\nEstimated primary com
 pletion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 meroprubart#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06979531
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07032662-10825@assetmemo.bio
DTSTAMP:20261121T005747Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Imeroprubart: Phase 2 readout est. (NCT07032662)
DESCRIPTION:Imeroprubart\, phase 2\, Chronic Inflammatory Demyelinating Pol
 yneuropathy.\nStudy: Imeroprubart in Adult Participants With Chronic Infla
 mmatory Demyelinating Polyneuropathy (CIDP)\nEstimated primary completion:
  August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/imeropr
 ubart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07032662
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816185-544@assetmemo.bio
DTSTAMP:20261121T005747Z
DTSTART;VALUE=DATE:20290128
DTEND;VALUE=DATE:20290129
SUMMARY:Mosliciguat: Phase 3 readout est. (NCT07816185)
DESCRIPTION:Mosliciguat\, phase 3\, Pulmonary Hypertension Associated with 
 Interstitial Lung Disease.\nStudy: A Phase 3 Trial of Inhaled Mosliciguat 
 in PH-ILD (PHrontier)\nEstimated primary completion: 28 January 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/mosliciguat#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07816185
URL:https://assetmemo.bio/drug/mosliciguat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286006-10825@assetmemo.bio
DTSTAMP:20261121T005747Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Imeroprubart: Phase 2 readout est. (NCT07286006)
DESCRIPTION:Imeroprubart\, phase 2\, Graves' Disease.\nStudy: A Long-Term E
 xtension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD
 )\nEstimated primary completion: March 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/imeroprubart#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07286006
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
